Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fimasartan vs Valsartan in Mild to Moderate Essential Hypertension
NCT00922441Phase 2Completed
- Sponsor
- Boryung
- Start
- Dec 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of fimasartan in essential hypertension (3 arms), sponsored by Boryung. Primary endpoint: Mean Change of Diastolic Blood Pressure at 8 weeks. Started Dec 2008; status: completed.
02
Drugs
fimasartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00922441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00922441.